Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.
First Graphene Limited strengthens its financial footing with a UK R&D tax rebate and expands its global footprint through new distribution agreements in India and Brazil.